A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 349, Issue 1, 1996, Pages 85-94

  Cunningham, Albert ^a   Klopman, Gilles ^b   Rosenkranz, Herbert S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Carcinogenicity; Metabolism; Structure activity; Tamoxifen; Toremifene

Indexed keywords

DRUG METABOLITE; HYDROXYLAMINE; TAMOXIFEN; TOREMIFENE;

ARTICLE; CARCINOGENICITY; CHEMICAL STRUCTURE; DATA BASE; DRUG METABOLISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

RODENTIA;

EID: 0030066508     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(95)00163-8     Document Type: Article

References (75)

1. Ashby, J. and Morrod, R.S. (1991) Detection of human carcinogens, Nature, 352, 185-186.
2. Ashby, J. and Tennant, R.W. (1991) Definitive relationships among chemical structure, carcinogenicity and mutagenicity of 301 chemicals tested by the U.S. National Toxicological Program, Mutation Res., 257, 229-306.
3. Bartsch, H. and Malaveille, C. (1989) Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series, Cell Biol. Toxicol., 5, 115-127.
4. Beland, F.A., Beranek, D.T., Dooley, K.L., Heflich, R.H. and Kadlubar, F.F. (1983) Arylamine-DNA adducts in vitro and in vivo: Their role in bacterial mutagenesis and urinary bladder carcinogenesis, Environ. Health Perspect., 49, 125-134.
5. Berthou, B.F. and Dreano, Y. (1993) High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites, J. Chromatogr. 616, 117-127.
6. Cater, D.A., Zeiger, E., Haworth, S., Lawlor, T., Mortelmans, K. and Speck, W. (1986) Comparative mutagenicity of aliphatic epoxides in Salmonella, Mutation Res., 172, 105-138.
7. Cohen, I., Rosen, J.D., Shapira, J., Cordoba, M., Gilboa, S., Altaras, M.M., Yigael, D. and Beyth, Y. (1992) Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer, Br. J. Obstet. Gynaecol., 100, 567-570.
8. Cunningham, A. and Rosenkranz, H.S. (1995) A study of the carcinogenicity of xenoestrogens: Metabolites of tamoxifen and toremifene. Technical Report No. CEOHT-95-01 to National Defense Center for Environmental Excellence, Available on World Wide Web: http://www.pitt.edu/~ jyzhang/ctc.html.
9. Davis, D.L., Bradlow, H.L., Wolff, M., Woodruff, T., Hoel, D.G. and Anton-Culver, H. (1993) Medical hypothesis: Xenoestrogens as preventable causes of breast cancer, Environ. Health Perspect., 101, 372-377.
10. Early Breast Cancer Trialists' Collaborative Group (1992a) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet, 339, 1-15.
11. Early Breast Cancer Trialists' Collaborative Group (1992b) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy, Lancet, 339, 71-85.
12. Ennever, F.K., Noonan, T.J. and Rosenkranz, H.S. (1987) The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans, Mutagenesis, 2, 73-78.
13. Fisher, B., Costantino, J., Redmond, C. et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N. Engl. J. Med., 320, 479-484.
14. Fornander, T., Rutqvist, L.E. and Cedemark, B. (1989) Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers, Lancet, i, 117-129.
15. Freese, E. (1963) Molecular mechanisms of mutations, In: J.H. Taylor (Ed.), Molecular Genetics, Part I, New York, Academic Press, pp. 207-269.
16. Gal, D.S., Kopel, S., Bashevkin, M., Lebowicz, J., Lev, R. and Tancer, M.L. (1991) Oncogenic potential of tamoxifen on endometrial of postmenopausal women with breast cancer-preliminary report, Gynecol. Oncol., 42, 120-123.
17. Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., deVeciana, M., Levinson, R., Hooper, N.K., Havender, W.R., Berstein, L., Peto, R., Pike, M.C. and Ames, B.N. (1984) A carcinogenic potency database of the standardized results of animal bioassays, Environ. Health Perspect., 58, 9-319.
18. Gold, L.S., deVeciana, M., Backman, G.M., Lopipero, M., Smith, M., Blumenthal, R., Levinson, R., Berstein, L. and Ames, B.N. (1986) Chronological supplement to the carcinogenic potency database: Standardized results of animal bioassays published through December 1982, Environ. Health Perspect., 67, 161-200.
19. Gold, L.S., Slone, T.H., Backman, G.M., Magaw, R., DaCosta, M., Lopipero, P., Blumenthal, M. and Ames, B.N. (1987) Second chronological supplement to the carcinogenic potency database: Standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986, Environ. Health Perspect., 74, 237-329.
20. Gold, L.S., Slone, T.H., Backman, G.M., Eisenberg, S., DaCosta, M., Wong, M., Manley, N.B., Rohrbach, L. and Ames, B.N. (1990) Third chronological supplement to the carcinogenic potency database: Standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987, Environ. Health Perspect., 84, 215-286.
21. Gold, L.S., Manely, N.B., Slone, T.H., Garfinkel, G.B., Rohrbach, L. and Ames B.N. (1993) The fifth plot of the carcinogenic potency database: Results of animal bioassays published in the general literature through 1988 and by the National toxicology program through 1989, Environ. Health Perspect., 100, 65-135.
22. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
23. Guillette, Jr., L.J., Gross, T.S., Masson, G.R., Matter, J.M., Percival, H.F. and Woodward, A.R. (1994) Developmental abnormalities of the gonad and abnormal sex hormone concentration in juvenile alligators from contaminated and control lakes in Florida, Environ. Health Perspect., 102, 680-688.
24. Gusburg, S.B. (1990) Tamoxifen for breast cancer: Associated endometrial cancer, Cancer, 65, 120-123.
25. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen, Cancer Res., 52: 1360-1363.
26. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L. Kaltenberg, O.P. Imondi, A.R. and Williams, G.M. (1993a) Major differences in the heptocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats, Cancer Res., 53: 4534-4541.
27. Hard, G.C., Williams, G.M. and Iatropoulos, M.J. (1993b) Tamoxifen and liver cancer, Lancet, 342, 444-445.
28. Haworth, S., Lawlor, T., Mortelmans, K., Speck, W. and Zeiger, E. (1983) Salmonella mutagenicity test results for 250 chemicals, Environ. Mutagen., 5 (Suppl. 1), 3-142.
29. Haworth, S., Lawlor, T., Zeiger, E., Lee, L. and Park, D. (1989) Mutagenic potential of ammonia-related aflotoxin reaction products in a model system, J. Am. Oil Chem. Soc., 66, 102-104.
30. Hirsimaki, P., Hirsimaki, L., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens, Arch. Toxicol., 67, 49-54.
31. Homesley, H.D., Shemano, I., Gams, R.A., Harry, D.S., Hickox, P.G., Rebar, R.W., Bump, R.C., Mullin, T.J., Wentz, A.C., O'Toole, R.V., Lovelace, J.V. and Lyden, C. (1993) Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women, Am. J. Clin. Oncol., 16, 117-122.
32. IARC (1987) Monograph on the Evaluation of Carcinogenic Risks to Humans: Genetic and Related Effects, Supplement 7. Overall Evaluation of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, International Agency for Research on Cancer, Lyon.
33. Kadlubar, F.F., Miller J.A. and Miller E.C. (1978) Guanyl O6-arylamination and O6-arylation of DNA by the carcinogen N-hydroxy-1-naphthylamine, Cancer Res., 38, 3628-3638.
34. Klopman, G. (1984) Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules, J. Am. Chem. Soc., 106, 7315-7321.
35. Klopman, G. (1992) MULTICASE 1. A hierarchical Computer Automated Structure Evaluation program, Quant. Struct. Activ. Relat., 11, 176-184.
36. Klopman, G. and Rosenkranz, H.S. (1984) Structural requirements for the mutagenicity of environmental nitroarenes, Mutation Res., 126, 227-238.
37. Klopman, G. and Rosenkranz, H.S. (1994) Prediction of carcinogenicity/mutagenicity using MULTICASE, Mutation Res., 305, 33-46.
38. Klopman, G., Dimayuge, M. and Talalous, J. (1994) META: 1. A program for the evaluation of metabolic transformations of Chemicals, J. Chem. Info. Comput. Sci., 34, 1320-1325.
39. Lawlor, T.E., Haworth, S.R., Zeiger, E., Park, D.L. and Lee, L.S. (1985) Mutagenic potential of ammonia-related aflotoxin reaction products in cottonseed meal, J. Am. Oil Chem. Soc., 62, 136-1138.
40. Lee, L., Rosenkranz, M.S., Buchanan, B.G., Mattison, D.M. and Klopman, G. Learning rules to predict rodent carcinogenicity of non-genotoxic chemicals, Mutation Res., in press.
41. Lerner, L.J., Jordan, V.C. (1990) Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture, Cancer Res., 50, 4177-4189.
42. Liehr, I.G., Avitts, T.A., Randerath, E. and Randerath, K. (1986) Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer, Proc. Natl. Acad. Sci USA, 83, 5301-5305.
43. Marselos, M. and Tomatis L. (1992) Diethylstilboestrol: I, pharmacology, toxicology and carcinogenicity in humans, Eur. J. Cancer, 28A: 1182-1189.
44. Martin, E.A., Turteltaub, K.W., Heydon, R., David, A., White, I.N.H. and Smith, L.L. (1995) Characterization of tamoxifen induced-DNA adducts formed in rat liver, Toxicol., 15, 152.
45. Montandon, F. and Williams, G.M. (1994) Comparison of DNA reactivity of the polyphenylethylene homonal agents diethyl-stilbestrol, tamoxifen and toremifene in rat and hamster liver, Arch. Toxicol., 68, 272-275.
46. Mortelmans, K., Haworth, S., Speck, W. and Zeiger, E. (1984) Mutagenicity testing of agent orange components and related chemicals, Toxicol. Appl. Pharm, 75, 137-146.
47. Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Trainer, B. and Zeiger, E. (1986) Salmonella mutagenicity tests. II. Results from testing 270 chemicals. Environ. Mutagen., 8 (Suppl. 7), 1-119.
48. 50: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments, Environ. Health Perspect., 58, 1-8.
49. 6-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen, Carcinogenesis, 15, 1487-1492.
50. Potter, G.A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism, Carcinogenesis, 15, 439-442.
51. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994a) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol, Carcinogenesis, 15, 797-800.
52. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxy-tamoxifen as a proximate metabolite, Carcinogenesis, 15, 2087-2094.
53. Reid, T., Moton, K., Wang, C. and King, C. (1984) Mutagenicity of azo dyes following metabolism by different reductive/oxidative systems, Environ. Mutagen., 6, 705-717.
54. Robinson S.P. and Jordan, V.C. (1988) Metabolism of steroid-modifying anticancer agents, Pharmacol Ther., 36, 41-103.
55. Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A. and Jordan, V.C. (1991) Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient, Drug Metab. Dispos., 19, 36-43.
56. Rosenkranz, H.S. and Klopman, G. (1990a) The structural basis of carcinogenicity in rodents of genotoxicants and non-genotoxicants, Mutation Res., 228, 105-124.
57. Rosenkranz, H.S. and Klopman, G. (1990b) The structural basis of the mutagenicity of chemicals in Salmonella typhimurium: The National Toxicology Program Data Base, Mutation Res., 228, 51-80.
58. Rosenkranz, H.S. and Klopman, G. (1990c) Prediction of the carcinogenicity in rodents of chemicals currently being tested by the US National Toxicology Program: structure-activity correlation, Mutagenesis, 5, 425-432.
59. Ruenitz, P.C. and Nanavati, N.T. (1990) Identification and distribution in the rat of acidic metabolites of tamoxifen, Drug Metab. Dispos., 18, 645-648.
60. Santti, R., Newbold, R.R., Makkela, S., Pylkkanen, L. and McLachian, J.A. (1994) Development estrogenization and prostatic neoplasia, Prostate, 24, 67-78.
61. Sharpe, R.M. and Skakkebaek, N.E. (1993) Are oestrogens involved in falling sperm count and disorders of the male reproductive tract?, Lancet, 341, 1392-1395.
62. Shelby, M.D. (1988) The genotoxicity of human carcinogens and its implications, Mutation Res., 204, 3-15.
63. Stenbygaard, C.E., Herrstedt, J., Thomsen, J.F., Svendsen, K.R., Engelholm, S.A. and Dombernowsky, P. (1993) Toremifene and tamoxifen in advanced breast cancer; A double-blind crossover trial, Breast Cancer Res. Treat., 25, 57-63.
64. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. and Smith L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s, Carcinogenesis, 15, 5-9.
65. Talafous, J., Sayre, L.M., Mieyal, J.J. and Klopman, G. (1994) META: 2. A dictionary model of mammalian xenobiotic metabolism, J. Chem. Info. Comput. Sci., 34, 1326-1333.
66. Tucker, M.J., Adam, H.K. and Patterson, J.S. (1984) Tamoxifen, In: Lawrence, D.R., McLean, A.E.M. and Weatherall, M. (Eds.), Safety Testing of New Drugs, New York, Academic Press, pp. 125-161.
67. Valavaara, R., Pyrhonen, S., Heckkinen, M., Rissanen, P., Blanco, G., Tholix, E., Nordman, E., Taskinen, P., Holsti, L. and Hajba, A. (1988) Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study, Eur. J. Cancer Clin. Oncol., 24, 785-790.
68. Vogel, C.L., Shemano, I., Schoenfelder, J., Gams, R.A. and Green, M.R. (1993) Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer, J. Clin. Oncol., 11: 345-350.
69. White, I.N.H., DeMatteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells, Carcinogenesis, 13, 2197-2203.
70. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat, Carcinogenesis, 14, 315-317.
71. Zeiger, E. (1990) Mutagenicity of 42 chemicals in Salmonella, Environ, Mol. Mutagen., 16 (Suppl. 13), 32-54.
72. Zeiger, E. and Haworth, S. (1985) Tests with a preincubation modification of the Salmonella I microsome assay, In: Ashby, J., de Serres, F.J., Draper, M., Ishidate, M., Jr., Margolin, B.H., Matter, B. and Shelby, M.D. (Eds.), Evaluation of Short-Term Tests for Carcinogenes. Amsterdam, Elsevier/North Holland, pp. 187-190.
73. Zeiger, E., Haworth, S., Mortelmans, K. and Speck, W. (1985) Mutagenicity testing of di(2-ethylhexyl)phthalate and related chemicals in Salmonella, Environ. Mutagen., 7, 213-232.
74. Zeiger, E., Anderson, B., Haworth, S., Lawior, T., Mortelmans, K. and Speck, W. (1987) Salmonella mutagenicity tests. III. Results from the testing of 225 chemicals, Environ. Mutagen., 9 (Suppl. 9), 1-109.
75. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T. and Mortelmans, K. (1988)v mutagenicity tests. IV. Results from the testing of 300 chemicals, Environ. Mutagen., 11 (Suppl. 12), 1-158.